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Abstract The structural requirements of vasoactive intestinal 
polypeptide (VIP) for receptor binding and cAMP production 
were studied in a cell line stable transfected with the cDNA for 
rat VIP receptor 1 (rVIPR 1). Using a number of chimeric 
constructs of VIP and the homologue peptide secretin, it was 
found that the N-terminal half of VIP (1-11) can be exchanged 
with the corresponding sequences in secretin with only modest 
influence on binding and activation, whereas the opposite 
chimeras with N-terminal VIP and C-terminal secretin were 
unable to bind to the VIP receptor. The data suggest that the C-
terminal region of VIP is important for receptor binding and 
activation. 
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1. Introduction 
Vasoactive intestinal peptide (VIP) is a 28-amino-acid pep-
tide that has a widespread occurrence in neurons of both the 
central and peripheral nervous system [1]. VIP seems to act as 
a neurotransmitter or neuromodulator in the brain, and phys-
iological studies have provided evidence that VIP is involved 
in the nervous control of smooth muscle activity, blood flow, 
and exo- and endocrine secretion [2]. VIP belongs to the VIP/ 
secretin family of peptides, which contains pituitary adenylate 
cyclase activating polypeptide (PACAP), PACAP-related pep-
tide, peptide with N-terminal histidine and C-terminal methio-
nine (PHM), glucagon, glucagon-like peptide-1 and -2 (GLP-1 
and -2), growth hormone releasing hormone (GHRH) and 
gastric inhibitory peptide (GIP) as reviewed by Campbell 
and Scanes [3]. All these peptides have sequence homology, 
with the highest identity found between VIP and PACAP 
(68%). The sequence identity between VIP and secretin is 
32%. NMR and circular dichroism studies have provided evi-
dence that VIP can be divided into two a-helical regions (res-
idues 9-17 and 23-28) connected by a hinge string [4,5]. The 
structure of VIP is in good correlation with structural NMR 
studies on other peptides in the family such as secretin, glu-
cagon, GLP-1, PACAP and GHRH [6-12]. 
The VIP receptors are seven transmembrane G-protein-
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coupled receptors belonging to a family consisting of the re-
ceptors for VIP, secretin, PACAP, GHRH, GIP, glucagon, 
GLP-1, calcitonin, parathyroid hormone and corticotropin 
releasing factor. Until now three types of the rat VIP receptor 
have been cloned, which are able to bind VIP with different 
affinity [13-16]. 
A number of structure-function studies have previously 
been performed using VIP analogues and various tissue prep-
arations [17-21]. It was found that both the N- and C-termi-
nal ends of the peptides are important for binding and func-
tion. Thus deletion of a single amino acid from the N-terminal 
part resulted in a considerable decrease in binding affinity and 
receptor activation. Likewise deletion of two C-terminal ami-
no acids caused a significant loss of binding and functional 
activity. Furthermore, it was demonstrated by Ala-scan that 
the residues Asp3, Phe6, Thr7, Tyr10, Tyr22 and Leu23 were 
important for the interaction with the receptors [20]. 
Cloning of the receptors has made it is possible to examine 
the structure-function relationship in mammalian cell lines 
expressing specifically the receptor of interest, thereby circum-
venting problems arising from the study of tissues that express 
more than one VIP receptor type. In order to elucidate which 
residues in VIP that are important for the interaction between 
the peptide and the rat VIP receptor 1, a number of chimeric 
peptides between VIP and secretin were made and the phar-
macology of these analogues was studied in a stable trans-
fected cell line expressing the receptor. 
2. Materials and methods 
2.1. Receptor constructs 
The VIP receptor 1 cDNA was obtained from Shigekazu Nagata 
(Osaka Bioscience Institute, 6-2-4 Furuedai, Suita, Osaka 565, Japan). 
The cDNA was subcloned as a Hindlll fragment into the expression 
vector pBW120 resulting in pBW190. pBW120 is a derivative of 
pBW87 [22] where the Hindlll site 3' to the ubiquitin promoter has 
been deleted. 
2.2. Peptide synthesis 
Synthetic VIP was purchased from Peninsula Lab., Inc. (USA). 
125I-labelled VIP was prepared by the chloramine-T method to a spe-
cific radio activity of 34 Bq/fmol. The sequences of rat VIP, rat se-
cretin and the VIP/secretin chimeric peptides shown in Fig. 1 were 
synthesised as previously described [23]. 
2.3. Cell culture and stable transfection 
Chinese hamster oocyte (CHO) 591 cells were grown at 5% C02 in 
RPMI-1640 medium supplemented with 10% fetal calf serum, 50 IU 
penicillin and 50 ug/ml streptomycin. The cell were cotransfected with 
20 (ig pBW190 and 2 ug pSV2Neo by the calcium phosphate proce-
dure as previously described [23]. Stable clones were selected in CHO 
medium containing 0.8 mg/ml G418. The clones were analysed for 
VIP binding and one clone (CHO-60-1A6) was selected for further 
analysis. 
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2.4. Binding of VIP and VIPisecretin analogues 
The cells (2X10B cells/well in 24-well culture dishes) were washed 
3 times in 500 ul of washing buffer (Krebs-Ringer-HEPES, pH 7.4, 
with 2.5 mM CaCb, 0.1% bovine serum albumin (BSA), 1 mg/ml 
bacitracin and 1 mM P-mercaptoethanol). The cells were incubated 
for 90 min at 37°C with 0.1 nM 126I-labelled VIP in incubation buffer 
(= washing buffer but with 1% BSA) in the presence of increasing 
amounts of unlabelled VIP or the chimeric peptides. The incubation 
was terminated by washing the cells twice in ice-cold washing buffer, 
after which the cells were harvested by 0.2 M NaOH and counted in a 
gammacounter. The amount of unspecific bound 125I-labelled VIP was 
determined as bound 125I-labelled VIP in the presence of 1 uM un-
labelled VIP. Binding data were fit to the following 4-parameter 1-step 
equation: Y=A+(B—A)l(l+XfICso)) to obtain the actual IC50, where 
A is non-specific binding, B is the maximum binding and X=log 
VIP(M). 
2.5. Intracellular cAMP assay 
cAMP assays were performed as previously described [23]. The cells 
(105 cells/well) were stimulated with increasing concentrations of VIP 
in the presence of 0.1 mM l-methyl-3-isobuthylxanthine (IBMX). The 
amount of cAMP produced by the cells was quantified using a cAMP 
radioimmunoassay kit from Amersham (UK). 
3. Results and discussion 
3.1. Characterisation of the binding of VIP, secretin and 
VIPisecretin chimeric peptides 
Neither secretin nor the three secretin analogues (RC162, 
RC163, RC164) could displace radiolabelled VIP from its 
receptor (Fig. 1). In a previous study [17], secretin was found 
to displace VIP in membrane preparation from rat cerebral 
cortex, although at rather high concentrations (IC50 = 250 
nM). In another study on a human glioma cell line [19], se-
cretin could only partially displace the VIP radioligand at the 
highest concentration used (1 uM). These discrepancies could 
be explained by the inhomogeneous nature of the cortical 
tissue. Thus the tissue preparation most likely contains other 
receptor types from the VIP/secretin receptor family that 
could bind VIP with low affinity. In contrast, the recombinant 
cell lines (and probably also the glioma cell line) express only 
one VIP receptor type and this could explain the differences in 
the ability of secretin to displace the VIP radioligand. The 
VIP receptor affinity for VIP (IC50 = 7.8 nM) corresponds to 
previously published results on the cloned VIP receptor 1 ex-
pressed in cell lines [13,14]. 
The binding of VIP and of the three VIP analogues 
(RC159, RC160, RC161) is shown in Fig. 2. The exchange 
in VIP of the two amino acids Ala(A)4Val(V)5 with 
Gly(G)4Thr(T)5 from secretin results in a marked decrease 
in affinity (IC50 = 392 nM, see Fig. 1). The affinity, however, 
can almost be normalised by introducing four more residues 
from secretin Ser(S)8Glu(E)9Leu(L)10Ser(S)n. Thus the affin-
ity for this VIP analogue in which the N-terminal half is 
secretin (IC5o = 40 nM) was found to be only 5-fold lower 
than that of VIP. Exchanging these four amino acids alone 
reduced the affinity by 2.5-fold as compared to VIP. 
3.2. Adenylate cyclase activation by the peptide analogues 
VIP stimulated the formation of cAMP in a dose-dependent 
manner with a EC50 of 0.16 ±0.02 nM (mean±SEM). The 
three VIP analogues stimulated the adenylate cyclase with 
maximal efficacy demonstrating that they are full agonists in 
this system (Fig. 3). RC161 and RC160 showed either no 
changes or only a slight decrease in potency (EC50 
0.22 ±0.07 nM and 0.40 ±0.12 nM) as compared to VIP, 
whereas the potency of RC159 was decreased by almost a 
decade (EC50 = 1.0±0.5 nM; see Fig. 3). The observed rank 
order of functionality corresponds to the rank order of the 
binding affinities. The observation that for all peptides the 
IC50S are much lower than the corresponding EC50 values 
can be explained by the presence of spare receptors, which 
has also been reported by Ciccarelli et al. [24]. 
Ala-scan of VIP [20] has indicated that Tyr10 is an impor-
Rat VIP: 
Rat Secretin: 
RC159 
RC160 
RC161 
HSDAVFTDNYTRLRKQMAVKKYLNSILN 
HSDGTFTSELSRLQDSARLQRLLQGLV 
HSD FTDNYTRLRKQMAVKKYLNSILN 
HSDAVFT RLRKQMAVKKYLNSILN 
HSD RLRKQMAVKKYLNSILN 
RC162 
RC163 
RC164 
HSD FTSELSRLQDSARLQRLLQGLV 
HSDGTFT RLQDSARLQRLLQGLV 
HSD^FT| j ]mRLRKQMAVKKYLNSlLN 
IC50 + SEM 
(nM) 
Hill coeffiecient 
±SD 
7.84 + 1.39 (n=5) 0.97 ±0.15 
ND 
392 ± 70 (n=5) 0.93 + 0.12 
22.8 ± 5.7 (n=5) 1.02 + 0.19 
40.4 ± 6.7 (n=8) 
ND 
1.02 ±0 .15 
ND 
ND 
Fig. 1. The sequences of rat VIP, rat secretin and the chimeric peptides are shown. VIP residues are presented with black letters on a white 
background and secretin residues are presented with white letters on a black background. Mean binding affinities (IC50) and Hill coefficients 
for VIP and VIP analogues to the VIP receptor 1 expressed in CHO cells are given. ND = no displacement by competitor. 
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Fig. 2. Competitive binding analysis of VIP, RC159, RC160 and 
RC161 to VIP receptor 1, stably expressed in CHO cells (CHO-60-
1A6). The binding profiles represent the mean±SEM of 5-8 sepa-
rate experiments performed in duplicate. IC50 values and Hill Coeffi-
cients are shown in Fig. 1. 
tant residue for the interaction of VIP with its receptor. Our 
data demonstrate, however, that four amino acids in this area, 
including Tyr1 0 could be substituted with only a modest effect 
on binding and activation of the receptor. In contrast the 
substitution of residues 4 and 5 with Gly and Thr resulted 
in a pronounced decrease in bo th binding affinity (50-fold) 
and potency (10-fold). This loss in activity could be restored 
by introducing residues 8-11 from secretin, thereby generating 
an analogue which from residue 1-11 is secretin and from 12-
28 is VIP. The finding that the secretin/VIP analogue binds 
the VIP receptor with only 5-fold lower affinity could indicate 
that the introduction of Gly and Thr in positions 4 and 5 
interferes with the structure of the molecule. The introduction 
of secretin residues from 8-11 in combination with Gly and 
Thr restores the structural determinant, which apparently is 
important for binding. The finding could be explained as fol-
lows: by exchanging Val with Thr a hydroxyl-group is intro-
duced, and if the hydroxyl group is unexposed to the solvent, 
it has to be hydrogen bound with a hydrogen donor in the 
pep tide. The further introduction of secretin sequences 
Ser(S)8Glu(E)9Leu(L)1 0Ser(S)n satisfies this possible hydro-
gen binding demand, and the overall structure of the peptide 
is therefore regenerated, resulting in high affinity for the VIP 
receptor. Thus disturbances in structural epitopes of the pep-
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Fig. 3. Activation of adenylate cyclase by VIP, RC159, RC160 and 
RC161 in intact CHO-60-1A6 cells. Data represent the mean±SEM 
of 6-7 experiments. 
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tides are important elements in the definition of pharmaco-
phoric elements of chimeric peptide studies. 
While the N-terminal half of VIP (residues 1-11) can be 
exchanged with the corresponding sequence in secretin with 
only modest influence on binding and functionality, the op-
posite chimera with N-terminal VIP and C-terminal secretin is 
unable to bind to the VIP receptor. This finding strongly 
suggests that the binding epitopes for VIP to its receptor 
are located in the C-terminal half (residue 12-28). Similar 
data were obtained using chimeric secretin and P A C A P pep-
tides to identify residues involved in binding [25]. Also in 
GLP-1 the binding epitope is located in the C-terminal half 
and the entire N-terminal half of GLP-1 could be exchanged 
with glucagon with only minor decreases in the binding affin-
ity [26].In glucagon, on the contrary, the N-terminal part of 
the peptide contains the binding epitopes emphasising the 
importance of studying each member of the VIP/secretin fam-
ily separately [26]. 
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